{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_references_citation in Reference Text / Citation (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333C
(2023)
Source URL:
First approved in 1968
Source:
NDA204426
Source URL:
Class:
MIXTURE
Status:
US Approved Rx
(2015)
Source:
BLA761036
(2015)
Source URL:
First approved in 2015
Source:
BLA761036
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2010)
Source:
BLA125320
(2010)
Source URL:
First approved in 2010
Source:
BLA125320
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2008)
Source:
BLA125249
(2008)
Source URL:
First approved in 2008
Source:
BLA125249
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2002)
Source:
BLA125057
(2002)
Source URL:
First approved in 2002
Source:
BLA125057
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1991)
Source:
BLA103353
(1991)
Source URL:
First approved in 1991
Source:
BLA103353
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT02295514: Not Applicable Interventional Completed Sepsis
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00707642: Phase 1 Interventional Completed West Nile Virus Disease
(2008)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:lusacomfar alfa [INN]
Source URL:
Class:
PROTEIN